Add a beneficial impact on climate change to the long list of benefits being attributed to GLP-1 agonist medicines. An unusual study presented at the European Society of Cardiology (ESC) congress in ...

With competition in the GLP-1 category increasingly cutthroat, Novo Nordisk has latched onto a real-world study that found its weight-loss drug Wegovy was better than Eli Lilly's rival Zepbound at ...

New and revised clinical guidance spanning dyslipidemia, cardiovascular disease in pregnancy, valvular heart disease, myocarditis and pericarditis, and mental health was released as part of ESC ...

A new meta-analysis from Mattia Galli, MD, PhD, et al., of 21 trials using eight different GLP1-RAs and with nearly 100,000 patients found "conclusive high-certainty evidence" that, vs. controls, the ...